ANTHRACYCLINE CARDIOTOXICITY: AN IN VITRO MODEL
蒽环类药物的心脏毒性:体外模型
基本信息
- 批准号:3174801
- 负责人:
- 金额:$ 9.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1983
- 资助国家:美国
- 起止时间:1983-07-01 至 1991-06-30
- 项目状态:已结题
- 来源:
- 关键词:Friend leukemia anthracyclines antineoplastics arrhythmia calcium transporting ATPase calmodulin carcinoma chemical structure function disease /disorder model doxorubicin drug adverse effect electron microscopy fibroblasts fluorescence microscopy heart cell heart contraction high performance liquid chromatography laboratory rat mitochondria muscle cells myocardium disorder neoplastic cell newborn animals oxidative phosphorylation tissue /cell culture
项目摘要
Although the anthracyclines, particularly Adriamycin (ADM), have
been shown to be useful in treating a broad spectrum of human
tumors, cardiotoxicity, often leading to fatal congestive heart
failure, remains a serious dose limiting side effect. In order to
study the mechanism of ADM-induced cardiomyopathy, we
developed a cardiac cell model in which several of the effect of
ADM described in vivo can be simulated in vitro. Using this
model we found that cardiac-muscle cells accumulate
significantly greater amounts of ADM and undergo increased
cellular damage as compared to cardiac-derived fibroblasts. This
observation was coupled with our findings that cardiac-muscle and
a number of carcinoma cell types and Friend leukemia cells
preferentially accumulate the mitochondrial localizing dye,
rhodamine 123. ADM and rhodamine 123 share in common that
they are both positively-charged at physiologic pH. Our working
hypothesis is that cardiac-muscle, a number of carcinoma cell
types and Friend leukemia cells have similar mechanisms for
enhanced accumulation of and sensitivity of positively-charged
anthracyclines and rhodamines.
Our specific aims are to determine (1) why cardiac-muscle, a
number of carcinoma cell lines and Friend leukemia cells
accumulate high amounts of positively-charged lipophilic
anthracyclines and rhodamines and (2) whether increased
membrane potentials contribute to increased drug accumulation
and sensitivity in these cell types. The ultimate goal is to
identify mechanisms responsible for differential sensitivity to
anthracyclines in order to prevent or reduce cardiotoxicity while
improving the antitumor effectiveness of known or heretofore
undiscovered anthracyclines and rhodamines. Using fluorescence
microscopy, laser flow cytometry, high pressure liquid
chromatography (HPLC), clonogenic assays and our computerized
video cardiac cell function analyzer, we plan to investigate
differential cellular accumulation and cytotoxicity of a variety of
anthracyclines, rhodamines, and other related compounds. Using
a number of modulators of resistance (calcium channel and
calmodulin inhibitors), we plan to identify those with least effect
on chronotropic and inotropic cardiac cell function and maximum
effect on overcoming resistance to anthracyclines and rhodamines
in cancer cells. By patch clamp technique, we will measure
membrane potentials in cardiac-muscle, carcinoma and ADM-
sensitive and resistant Friend leukemia cells and assess its
importance relative to drug accumulation and chemosensitivity.
虽然蒽环类药物,特别是阿霉素(ADM),
已被证明对治疗广谱的人类
肿瘤,心脏毒性,经常导致致命的充血性心脏
失败,仍然是一个严重的剂量限制副作用。为了
研究阿霉素性心肌病的发病机制
开发了一种心肌细胞模型,在该模型中,
体内描述的ADM可以在体外模拟。使用这个
模型中,我们发现心肌细胞堆积
显著增加了ADM的数量,并经历了
与心脏来源的成纤维细胞相比,细胞损伤。这
观察与我们的发现相结合,心肌和
多种癌细胞类型与Friend白血病细胞
优先积累线粒体定位染料,
罗丹明123号。ADM和罗丹明123的共同之处是
它们在生理pH下都带正电荷。我们的工作
假说是心肌、癌细胞数量众多
类型和朋友白血病细胞具有类似的机制
增强了正电荷的积累和灵敏度
蒽环类和罗丹明类药物。
我们的具体目标是确定(1)为什么心肌,一个
癌细胞系和Friend白血病细胞的数量
积累大量带正电荷的亲脂性
以及(2)是否增加。
膜电位有助于增加药物蓄积
以及对这些细胞类型的敏感性。最终目标是
找出导致差异敏感性的机制
在预防或减少心脏毒性的同时,使用蒽环类药物
提高已知或迄今已知的抗肿瘤药物的有效性
未发现的蒽环类药物和罗丹明类药物。使用荧光法
显微镜、激光流式细胞术、高压液体
高效液相色谱、克隆分析和我们的计算机化
视频心脏细胞功能分析仪,我们计划调查
不同类型药物的细胞蓄积和细胞毒性差异
蒽环类、罗丹明和其他相关化合物。vbl.使用
多种抗性调节剂(钙通道和
钙调蛋白抑制剂),我们计划找出那些效果最差的
论变时性和变力性心肌细胞的功能和最大
克服对蒽环类药物和罗丹明类药物耐药性的效果
在癌细胞中。通过膜片钳技术,我们将测量
心肌、肿瘤和ADM的膜电位
敏感和耐药的Friend白血病细胞并评估其
与药物积累和药物敏感性相关的重要性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THEODORE J LAMPIDIS其他文献
THEODORE J LAMPIDIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THEODORE J LAMPIDIS', 18)}}的其他基金
ANTHRACYCLINE CARDIOTOXICITY: AN IN VITRO MODEL
蒽环类药物的心脏毒性:体外模型
- 批准号:
3174800 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
Role of Mitochondria and Glycolysis in Tumor Cell MDR
线粒体和糖酵解在肿瘤细胞 MDR 中的作用
- 批准号:
6861020 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
ANTHRACYCLINE CARDIOTOXICITY: AN IN VITRO MODEL
蒽环类药物的心脏毒性:体外模型
- 批准号:
3174794 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
Role of Mitochondria and Glycolysis in Tumor Cell MDR
线粒体和糖酵解在肿瘤细胞 MDR 中的作用
- 批准号:
6512472 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
DRUG SELECTIVITY IN CARDIAC AND MDR TUMOR CELLS
心脏和 MDR 肿瘤细胞的药物选择性
- 批准号:
2089227 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
PROBING MDR & MRP WITH SIMPLE COMPOUNDS & ANTHRACYCLINES
探索MDR
- 批准号:
2393426 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
Anti-tumor Activity of Sugar Analogs via Blocking Glycolysis vs Glycosylation
糖类似物通过阻断糖酵解与糖基化的抗肿瘤活性
- 批准号:
8092860 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
Anti-tumor Activity of Sugar Analogs via Blocking Glycolysis vs Glycosylation
糖类似物通过阻断糖酵解与糖基化的抗肿瘤活性
- 批准号:
7866499 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
Anti-tumor Activity of Sugar Analogs via Blocking Glycolysis vs Glycosylation
糖类似物通过阻断糖酵解与糖基化的抗肿瘤活性
- 批准号:
7462352 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
ANTHRACYCLINE INDUCED CARDIAC TOXICITY: AN IN VITRO MODE
蒽环类药物引起的心脏毒性:体外模式
- 批准号:
3174799 - 财政年份:1983
- 资助金额:
$ 9.43万 - 项目类别:
相似海外基金
RUI: BIOPOLYMER - BIObricks POLYketide Metabolic EngineeRing platform for unraveling the biosynthesis of higher anthracyclines
RUI:BIOPOLYMER - BIObricks 聚酮化合物代谢工程平台,用于揭示高级蒽环类药物的生物合成
- 批准号:
2321976 - 财政年份:2024
- 资助金额:
$ 9.43万 - 项目类别:
Standard Grant
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
- 批准号:
10378678 - 财政年份:2021
- 资助金额:
$ 9.43万 - 项目类别:
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
- 批准号:
10195941 - 财政年份:2021
- 资助金额:
$ 9.43万 - 项目类别:
Validation and Implementation of Polygenic-Risk Prediction Models for Anthracyclines and Cisplatin in Pediatric Oncology
儿科肿瘤学中蒽环类药物和顺铂多基因风险预测模型的验证和实施
- 批准号:
429174 - 财政年份:2019
- 资助金额:
$ 9.43万 - 项目类别:
Studentship Programs
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
- 批准号:
9351286 - 财政年份:2016
- 资助金额:
$ 9.43万 - 项目类别:
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
- 批准号:
9176736 - 财政年份:2016
- 资助金额:
$ 9.43万 - 项目类别:
Linking defects in the uptake transporter OCT1 with cancer patients resistance towards anthracyclines
将摄取转运蛋白 OCT1 的缺陷与癌症患者对蒽环类药物的耐药性联系起来
- 批准号:
357190 - 财政年份:2016
- 资助金额:
$ 9.43万 - 项目类别:
Operating Grants
Anthracyclines disrupt Ca2+ signalling in cardiomyocytes: a contribution to cardiac toxicity
蒽环类药物破坏心肌细胞中的 Ca2 信号传导:导致心脏毒性
- 批准号:
nhmrc : 1021342 - 财政年份:2012
- 资助金额:
$ 9.43万 - 项目类别:
Project Grants
Examination of the Molecular Pharmacology of Anthracyclines Induced via their Interaction with Iron
通过与铁相互作用诱导的蒽环类药物的分子药理学研究
- 批准号:
nhmrc : 457310 - 财政年份:2007
- 资助金额:
$ 9.43万 - 项目类别:
NHMRC Project Grants














{{item.name}}会员




